These considerations are particularly relevant as health systems, payers, and clinicians evaluate access to GLP-1RAs for people with T2D and comorbid obesity
D-carnitine is inactive and therefore of no use
Szsz, et al., 'Antidiabetic GLP-1 Receptor Agonists Have Neuroprotective Properties in Experimental Animal Models of Alzheimer's Disease', Pharmaceuticals , vol
47 The surveillance programme starts with endoscopic biopsy of the Barretts mucosa: four quadrant biopsies at 2 cm intervals in patients with non-dysplastic BO, and four quadrant biopsies at 1 cm intervals in patients with known dysplastic BO
The ESSENCE trial 240-week readout in 2028 will be a landmark, but longer follow-up and adequately powered studies in higher-risk populations (F3-F4 fibrosis) remain priorities
Tapering Schedule It's a good idea to establish a fluoxetine withdrawal timeline